Topics

FDA

The U.S. Food and Drug Administration (FDA) is the federal agency responsible for regulating food, drugs, and medical devices. On November 10, 2026, the FDA warned that GLP‑1 drugs, including Ozempic and Zepbound, may cause a rare vision loss condition (NAION), citing over 125 trials showing about six cases per 100,000 users after one year.

8 stories·Updated Nov 10

What to know

FDA warns of NAION risk with GLP‑1 receptor agonists Nov 10
Over 125 trials show about 6 cases per 100,000 users after one year Nov 10
FDA added new warnings to Ozempic, Zepbound, Wegovy and Mounjaro for NAION risk. Nov 9
Patients should watch for sudden vision loss or blurred vision and report changes immediately. Nov 9
Ascend Laboratories recalled 3,744 bottles of amlodipine/olmesartan tablets due to failed dissolution specifications. Nov 2

Timeline

Nov 10, 2026

Health
FDA warns GLP‑1 drugs may cause rare vision loss

Nov 10·2 min read
Nov 9, 2026

Health
FDA warns Ozempic and Zepbound may cause rare eye condition

Nov 9·3 min read
Nov 2, 2026

Health
Olmesartan recall spreads to thousands of blood‑pressure bottles

Nov 2·2 min read
Oct 31, 2026

Health
Once Upon a Farm recalls Tractor Wheels toddler bars over choking hazard

Oct 31·2 min read
Apr 17, 2026

Health
Regulatory shift on peptides could lift Hims & Hers stock

Apr 17·3 min read
Dec 22, 2025

Health
Novo Nordisk’s Wegovy pill approved by FDA

Dec 22·2 min read
Jun 9, 2025

Entertainment
Egg recall expands after salmonella outbreak sickens 79 people

Jun 9·1 min read
Jun 9, 2025

Entertainment
Egg recall affects nine states after salmonella outbreak

Jun 9·1 min read